ICIs targeting programmed cell death protein (PD- 1) and its ligand PD-L1 have demonstrated significant efficacy in tumors with high mutational burden and neo-antigen loads, including DNA-deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) CRC [5, 6]. The gene discussed is RPL17; the disease is colorectal carcinoma.